title: [Management of low-risk prostate cancer].
abstract: BACKGROUND
  The widespread use of prostate cancer screening has led to a stage migration resulting in an increase in the diagnosis of low-risk disease, which currently accounts for 40-50% of diagnosed forms. New therapeutic strategies have been developed in order to minimize the risk of overtreatment.
  
  
  METHODS
  A systematic review of the literature over the past 20 years was performed using the Medline database. The literature selection was based on evidence and practical considerations.
  
  
  RESULTS
  Low-risk tumors are conventionally defined by the d'Amico classification. The use of multiparametric MRI helps to better characterize these tumors. The contribution of molecular biology remains to be determined in clinical practice. Novel therapeutic options for low-risk disease are currently being evaluated.
  
  
  CONCLUSIONS
  The new therapeutic strategies are evolving. They seek to reduce overtreatment without compromising oncological success.
authors.affiliation: Université Paris Descartes, institut Montsouris, 42, boulevard Jourdan, 75014 Paris, France; Comité de cancérologie de l'AFU, France. Electronic address: francois.rozet@imm.fr.
authors.forename: F
authors.initials: F
authors.lastname: Rozet
authors.affiliation: Hôpital Nord, CHU de Marseille, 416, chemin Madrague-Ville, 13015 Marseille, France; Comité de cancérologie de l'AFU, France.
authors.forename: C
authors.initials: C
authors.lastname: Bastide
authors.affiliation: Institut Curie, 26, rue Ulm, 75005 Paris, France; Comité de cancérologie de l'AFU, France.
authors.forename: P
authors.initials: P
authors.lastname: Beuzeboc
authors.affiliation: CHU de Dijon, 1, boulevard Jeanne-d'Arc, 21000 Dijon, France; Comité de cancérologie de l'AFU, France.
authors.forename: L
authors.initials: L
authors.lastname: Cormier
authors.affiliation: CHU Bretonneau, 2, boulevard Tonnellé, 37000 Tours, France; Comité de cancérologie de l'AFU, France.
authors.forename: G
authors.initials: G
authors.lastname: Fromont
authors.affiliation: Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France; Comité de cancérologie de l'AFU, France.
authors.forename: C
authors.initials: C
authors.lastname: Hennequin
authors.affiliation: Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France; Comité de cancérologie de l'AFU, France.
authors.forename: P
authors.initials: P
authors.lastname: Mongiat-Artus
authors.affiliation: Hôpital Cochin, 27, rue Faubourg Saint-Jacques, 75014 Paris, France; Comité de cancérologie de l'AFU, France.
authors.forename: M
authors.initials: M
authors.lastname: Peyromaure
authors.affiliation: Hôpital Pitié-Salpêtrière, 47, boulevard de l'hôpital, 75013 Paris, France; Comité de cancérologie de l'AFU, France.
authors.forename: R
authors.initials: R
authors.lastname: Renard-Penna
authors.affiliation: Institut Bergonié, 229, cours Argonne, 33000 Bordeaux, France; Comité de cancérologie de l'AFU, France.
authors.forename: P
authors.initials: P
authors.lastname: Richaud
authors.affiliation: Hôpital Henri-Mondor, 51, avenue Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France; Comité de cancérologie de l'AFU, France.
authors.forename: L
authors.initials: L
authors.lastname: Salomon
authors.affiliation: Hôpital de Rangueil, CHU de Toulouse, 1, avenue Professeur Jean-Poulhès, 31059 Toulouse cedex 9, France; Comité de cancérologie de l'AFU, France.
authors.forename: M
authors.initials: M
authors.lastname: Soulié
mesh_terms: D018450:Disease Progression; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D018579:Patient Selection; D017430:Prostate-Specific Antigen; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000145:classification* / Q000473:pathology / Q000628:therapy*; D055502:Secondary Prevention; D057832:Watchful Waiting
chemical_list: D017430:Prostate-Specific Antigen
keywords: Active surveillance; Cancer de la prostate à faible risque; Focal therapy; Low-risk prostate cancer; Prostatectomie totale; Radiation therapy; Radical prostatectomy; Radiothérapie; Surveillance active; Traitement focal